May 2024: new data on the WID-qEC test

A new publication from the EUTOPS team describes the high sensitivity and specificity of the WID-qEC irrespective of sample collection device and medium, sample collector and precise sampling site.

April 2024: Dr Chiara Herzog awarded the AGO Austria Young Scientist Award 2024

EUTOPS publishes new research showing that e-cigarette users with a limited smoking history experience similar DNA changes to specific cheek cells as smokers.

March 2024: Similar DNA changes found in cells of both smokers and e-cigarette users

EUTOPS publishes new research showing that e-cigarette users with a limited smoking history experience similar DNA changes to specific cheek cells as smokers.

February 2024: Framework for Validating Biomarkers of Aging

EUTOPS’ lead Computational Biologist – Chiara Herzog, PhD – joins Mahdi Moqri and Jesse Poganik from Harvard Medical School in leading this Nature Review article on Validating Biomarkers of Aging. The article proposes a framework for the future validation of aging biomarkers with a view to their translation in to clinically actionable tools.

November 2023: Simple new uterine cancer test could prevent thousands from needing surgical diagnostic procedures

A new publication by Prof Martin Widschwendter and his team reports on a test for the detection of uterine cancer that outperforms currently used methods in peri- and postmenopausal women with abnormal vaginal bleeding.

October 2023: New insights for breast cancer risk stratification

A new paper from the EUTOPS team has been published in Precision Oncology highlighting the dynamic interplay between genetics and nonheritable factors captured on the epigenome, varying across different sample types, and indicating breast cancer risk.

October 2023: New data on plasma cell-free DNA methylation markers of ovarian cancer

The EUTOPS team’s new paper evaluates circulating cell-free DNA methylation markers that could be used to improve diagnosis and earlier detection of ovarian cancers. The data suggest that analysis of cell-free DNA methylation, alone or combined with the existing CA125 marker, could help to detect ovarian cancers earlier and may reduce mortality from the disease.

September 2023: European Research Council Proof of Concept award for cancer prevention research

Martin Widschwendter, Professor of Oncology and Prevention at the University of Innsbruck, has been awarded Proof of Concept funding from the European Research Council (ERC) for his pioneering work in preventive medicine. The new project is based on his ERC Advanced Grant and is intended to further exploit his work in cancer prevention.

August 2023: Using biomarkers to combat age-related diseases

Read our new publication in Cell in collaboration with the international Biomarkers of Aging Consortium.

May 2023: EUTOPS postdoctoral researcher Chiara Herzog receives the Ernst Brandl Prize

EUTOPS postdoctoral researcher Chiara Herzog has received the Ernst Brandl Prize of €4,000 for her work on the development and validation of a novel epigenetic test – the WID-qEC test – for the early detection of endometrial cancer. Chiara is an integral member of the EUTOPS team, working on computational aspects of epigenetics in cancer development and prevention and in ageing research.

February 2023: A new molecular test captures Human Papilloma Virus (HPV) induced changes in a woman’s epigenome

A new publication from Professor Martin Widschwendter and the EUTOPS team in the International Journal of Cancer describes the development of cervical cancer as a result of Human Papilloma Virus (HPV) infection.

February, October, and December 2022: Women’s cancer detection and risk prediction – four cancers, one test

The EUTOPS team presents four publications demonstrating that DNA methylation signature assessment using methylation array analysis in cervical screening samples detects and likely predicts the risk for all four major women’s cancers: breast, ovarian, womb and cervical cancer.

October 2022: New cervical screening test could predict cell changes years before they happen

A new publication from Professor Martin Widschwendter and the EUTOPS team in Genome Medicine describes a new molecular test that can identify 55% of those with a normal cervical smear result who will go on to develop advanced cell changes or cancer within 4 years.

August 2022: New molecular test proves reliable for early detection of womb cancer

Our paper describing a new test that accurately identifies women with womb cancer appears in Journal of Clinical Oncology today.

June 2022: Breast cancer prevention with antiprogestins and the WID-Breast29 index

Our paper describing individualised breast cancer prevention and risk monitoring using antiprogestins and the epigenetic WID-Breast29 index appears in Genome Medicine today.

February 2022: Publication of WID epigenetic clocks

Today we published the WID epigenetic clocks (WID-age and WID-relative epithelial age, WID-REA) in Genome Biology.

EUTOPS Institute

Our vision is to integrate cutting-edge research in systems biology and oncology to enable real-world implementation of the concepts of P4 medicine (predictive, preventive, personalised and participatory) and drastically reduce cancer mortality.

Meet the Team

We are a dynamic and international team with wide range of expertise.